P Queirolo, M Cinquini, G Argenziano, F Bassetto, P Bossi, A Boutros, C Clemente, V de Giorgi, M Del Vecchio, R Patuzzo, E Pennachioli, K Peris, P Quaglino, A Reali, I Zalaudek, F Spagnolo
Cutaneous squamous cell carcinoma (CSCC) accounts for ∼20%-25% of all skin tumors. Its precise incidence is often challenging to determine due to limited statistics and its incorporation with mucosal forms. While most cases have a favorable prognosis, challenges arise in patients presenting with locally advanced or metastatic forms, mainly appearing in immunocompromised patients, solid organ transplantation recipients, or those facing social difficulties. Traditionally, chemotherapy and targeted therapy were the mainstays for advanced cases, but recent approvals of immunotherapeutic agents like cemiplimab and pembrolizumab have revolutionized treatment options...
April 29, 2024: ESMO Open